219 reports of this reaction
2.2% of all VONOPRAZAN FUMARATE reports
#7 most reported adverse reaction
GASTROOESOPHAGEAL REFLUX DISEASE is the #7 most commonly reported adverse reaction for VONOPRAZAN FUMARATE. There are 219 FDA adverse event reports linking VONOPRAZAN FUMARATE to GASTROOESOPHAGEAL REFLUX DISEASE. This represents approximately 2.2% of all 9,763 adverse event reports for this drug.
Patients taking VONOPRAZAN FUMARATE who experience gastrooesophageal reflux disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GASTROOESOPHAGEAL REFLUX DISEASE is a less commonly reported adverse event for VONOPRAZAN FUMARATE, but still significant enough to appear in the safety profile.
In addition to gastrooesophageal reflux disease, the following adverse reactions have been reported for VONOPRAZAN FUMARATE:
The following drugs have also been linked to gastrooesophageal reflux disease in FDA adverse event reports:
GASTROOESOPHAGEAL REFLUX DISEASE has been reported as an adverse event in 219 FDA reports for VONOPRAZAN FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GASTROOESOPHAGEAL REFLUX DISEASE accounts for approximately 2.2% of all adverse event reports for VONOPRAZAN FUMARATE, making it a notable side effect.
If you experience gastrooesophageal reflux disease while taking VONOPRAZAN FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.